Document Detail


Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients.
MedLine Citation:
PMID:  15363819     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Peripheral vasculature undergoes extensive vascular remodeling in the hypertensive state. Regulation of extracellular matrix turnover by the matrix metalloproteinase (MMP) system is an important step in the vascular remodeling process. However, the expression pattern of the vascular MMP system in human hypertension remained unknown. METHODS AND RESULTS: Internal mammary artery specimens were obtained from normotensive (n = 13) and hypertensive (n = 19) patients undergoing coronary artery bypass grafting surgery. Zymographic analysis indicated a threefold decrease in total gelatinolytic activity of MMP-2 and MMP-9 in hypertension. MMP-1 activity was also decreased by fourfold without a significant change in protein levels. Tissue levels of extracellular matrix inducer protein (EMMPRIN), MMP activator protein (MT1-MMP), MMP-1, MMP-2, and MMP-9, as well as tissue inhibitors of MMPs (TIMP-1 and TIMP-2) were assessed by immunoblotting and yielded a significant decrease in MMP-9, EMMPRIN, and MT1-MMP levels in hypertension. In addition, measurement of plasma markers of collagen synthesis (procollagen type I amino-terminal propeptide [PINP]) and collagen degradation (carboxy-terminal telopeptide of collagen type I [ICTP]) indicated no difference in PINP levels but suppressed degradation of collagen in hypertension. Evaluation of profibrotic growth factors demonstrated higher levels of fibroblast growth factor (FGF)-2 in tissue preparations from hypertensive patients but no difference in transforming growth factor-beta1 levels. CONCLUSIONS: These findings demonstrate that not only MMP-1 and MMP-9, but MMP inducer and activator proteins are also downregulated in the hypertensive state. Augmented FGF-2 levels may contribute to parallel decreases in MMP activity and MMP induction system resulting in enhanced collagen deposition in hypertension.
Authors:
Adviye Ergul; Vera Portik-Dobos; Jimmie Hutchinson; Jennifer Franco; Mark P Anstadt
Related Documents :
23701259 - Photocontrol of solvent responsiveness of structural colored balloons.
2780119 - The hypertensive adolescent.
4085729 - Some data on hypertension control in italy. epidemiological collaborative group.
8863889 - A case of guillain-barré syndrome accompanied by sympathetic overactivity and hypertens...
15831089 - 5-ht in systemic hypertension: foe, friend or fantasy?
6736839 - Vector u loop in normal and hypertensive subjects.
11981289 - Pediatric hypertension: recent literature.
21679139 - Microaspiration in intubated critically ill patients: diagnosis and prevention.
19646369 - Sympathetic and parasympathetic responses to specific diversified adjustments to chirop...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of hypertension     Volume:  17     ISSN:  0895-7061     ISO Abbreviation:  Am. J. Hypertens.     Publication Date:  2004 Sep 
Date Detail:
Created Date:  2004-09-14     Completed Date:  2004-12-16     Revised Date:  2009-02-24    
Medline Journal Info:
Nlm Unique ID:  8803676     Medline TA:  Am J Hypertens     Country:  United States    
Other Details:
Languages:  eng     Pagination:  775-82     Citation Subset:  IM    
Copyright Information:
Copyright 2004 American Journal of Hypertension, Ltd.
Affiliation:
Program in Clinical and Experimental Therapeutics, University of Georgia College of Pharmacy, Medical College of Georgia, Augusta, Georgia 30912, USA. aergul@mail.mcg.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antigens, CD / metabolism
Antigens, CD147
Antigens, Neoplasm / metabolism
Coronary Artery Bypass
Down-Regulation
Extracellular Matrix / metabolism
Female
Fibroblast Growth Factor 2 / metabolism
Humans
Hypertension / metabolism*
Male
Mammary Arteries / metabolism
Matrix Metalloproteinase 1 / metabolism
Matrix Metalloproteinase 2 / metabolism
Matrix Metalloproteinase 9 / metabolism
Matrix Metalloproteinases / metabolism*
Matrix Metalloproteinases, Membrane-Associated
Metalloendopeptidases / metabolism
Middle Aged
Tissue Inhibitor of Metalloproteinase-1 / metabolism*
Tissue Inhibitor of Metalloproteinase-2 / metabolism*
Transforming Growth Factor beta / metabolism
Transforming Growth Factor beta1
Chemical
Reg. No./Substance:
0/Antigens, CD; 0/Antigens, Neoplasm; 0/BSG protein, human; 0/TGFB1 protein, human; 0/Tissue Inhibitor of Metalloproteinase-1; 0/Transforming Growth Factor beta; 0/Transforming Growth Factor beta1; 103107-01-3/Fibroblast Growth Factor 2; 127497-59-0/Tissue Inhibitor of Metalloproteinase-2; 136894-56-9/Antigens, CD147; EC 3.4.24.-/Matrix Metalloproteinases; EC 3.4.24.-/Matrix Metalloproteinases, Membrane-Associated; EC 3.4.24.-/Metalloendopeptidases; EC 3.4.24.24/Matrix Metalloproteinase 2; EC 3.4.24.35/Matrix Metalloproteinase 9; EC 3.4.24.7/Matrix Metalloproteinase 1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hyper...
Next Document:  Erythropoietin and obstructive sleep apnea.